Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).

Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Sutherland ER, Mastey V.

J Am Acad Dermatol. 2016 Sep;75(3):506-15. doi: 10.1016/j.jaad.2016.04.054.

PMID:
27268421
2.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.

Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5.

PMID:
27130691
3.

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.

Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland ER.

JAMA. 2016 Feb 2;315(5):469-79. doi: 10.1001/jama.2015.19330.

PMID:
26836729
4.

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M.

Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8.

PMID:
26454361
5.

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H.

Am J Respir Crit Care Med. 2015 May 1;191(9):1001-11. doi: 10.1164/rccm.201405-0992OC.

PMID:
25695403
6.

Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.

Putcha N, Han MK, Martinez CH, Foreman MG, Anzueto AR, Casaburi R, Cho MH, Hanania NA, Hersh CP, Kinney GL, Make BJ, Steiner RM, Lutz SM, Thomashow BM, Williams AA, Bhatt SP, Beaty TH, Bowler RP, Ramsdell JW, Curtis JL, Everett D, Hokanson JE, Lynch DA, Sutherland ER, Silverman EK, Crapo JD, Wise RA, Regan EA, Hansel NN; the COPDGene® Investigators..

Chronic Obstr Pulm Dis. 2014;1(1):105-114.

7.

Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene.

Kim V, Crapo J, Zhao H, Jones PW, Silverman EK, Comellas A, Make BJ, Criner GJ; COPDGene Investigators..

Ann Am Thorac Soc. 2015 Mar;12(3):332-9. doi: 10.1513/AnnalsATS.201411-518OC.

8.

Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma.

Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock BD, Douda DN, Tabet Y, Khaddaj-Mallat R, Sirois M, Sirois C, Rizcallah E, Rousseau E, Martin R, Sutherland ER, Castro M, Jarjour NN, Israel E, Levy BD; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network..

Am J Respir Crit Care Med. 2014 Oct 15;190(8):886-97. doi: 10.1164/rccm.201403-0544OC.

9.

Is there a link between obesity and asthma?

Kim SH, Sutherland ER, Gelfand EW.

Allergy Asthma Immunol Res. 2014 May;6(3):189-95. doi: 10.4168/aair.2014.6.3.189. Review.

10.

Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial.

Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, Kazani SD, Moore WC, Moy J, Sorkness CA, Avila P, Bacharier LB, Bleecker E, Boushey HA, Chmiel J, Fitzpatrick AM, Gentile D, Hundal M, Israel E, Kraft M, Krishnan JA, LaForce C, Lazarus SC, Lemanske R, Lugogo N, Martin RJ, Mauger DT, Naureckas E, Peters SP, Phipatanakul W, Que LG, Sheshadri A, Smith L, Solway J, Sullivan-Vedder L, Sumino K, Wechsler ME, Wenzel S, White SR, Sutherland ER; National Heart, Lung, and Blood Institute’s AsthmaNet..

JAMA. 2014 May;311(20):2083-91. doi: 10.1001/jama.2014.5052.

11.

Linking obesity and asthma.

Sutherland ER.

Ann N Y Acad Sci. 2014 Apr;1311:31-41. doi: 10.1111/nyas.12357. Review.

12.

Leukotriene B4 receptor 1 is differentially expressed on peripheral T cells of steroid-sensitive and -resistant asthmatics.

Chung EH, Jia Y, Ohnishi H, Takeda K, Leung DY, Sutherland ER, Dakhama A, Martin RJ, Gelfand EW.

Ann Allergy Asthma Immunol. 2014 Mar;112(3):211-216.e1. doi: 10.1016/j.anai.2013.12.006.

13.

Designing clinical trials to address the needs of childhood and adult asthma: the National Heart, Lung, and Blood Institute's AsthmaNet.

Sutherland ER, Busse WW; National Heart, Lung, and Blood Institute's AsthmaNet..

J Allergy Clin Immunol. 2014 Jan;133(1):34-8.e1. doi: 10.1016/j.jaci.2013.10.025. Review.

14.

Predictors of response to tiotropium versus salmeterol in asthmatic adults.

Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Craig T, Denlinger LC, Engle LL, Dimango EA, Israel E, Kraft M, Lazarus SC, Lemanske RF Jr, Lugogo N, Martin RJ, Meyers DA, Ramsdell J, Sorkness CA, Sutherland ER, Wasserman SI, Walter MJ, Wechsler ME, Chinchilli VM, Szefler SJ; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network..

J Allergy Clin Immunol. 2013 Nov;132(5):1068-1074.e1. doi: 10.1016/j.jaci.2013.08.003.

15.

The effects of airway microbiome on corticosteroid responsiveness in asthma.

Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, Good JT Jr, Gelfand EW, Martin RJ, Leung DY.

Am J Respir Crit Care Med. 2013 Nov 15;188(10):1193-201. doi: 10.1164/rccm.201304-0775OC.

16.

IL-13-producing BLT1-positive CD8 cells are increased in asthma and are associated with airway obstruction.

Dakhama A, Collins ML, Ohnishi H, Goleva E, Leung DY, Alam R, Sutherland ER, Martin RJ, Gelfand EW.

Allergy. 2013;68(5):666-73. doi: 10.1111/all.12135.

17.

Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances.

Carolan BJ, Sutherland ER.

J Allergy Clin Immunol. 2013 Mar;131(3):627-34; quiz 635. doi: 10.1016/j.jaci.2013.01.010. Review.

PMID:
23360757
18.

Modeling the impact of increased adherence to asthma therapy.

Schlender A, Alperin PE, Grossman HL, Sutherland ER.

PLoS One. 2012;7(12):e51139. doi: 10.1371/journal.pone.0051139.

19.

Obesity impairs apoptotic cell clearance in asthma.

Fernandez-Boyanapalli R, Goleva E, Kolakowski C, Min E, Day B, Leung DY, Riches DW, Bratton DL, Sutherland ER.

J Allergy Clin Immunol. 2013 Apr;131(4):1041-7, 1047.e1-3. doi: 10.1016/j.jaci.2012.09.028.

20.

P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy.

Denlinger LC, Manthei DM, Seibold MA, Ahn K, Bleecker E, Boushey HA, Calhoun WJ, Castro M, Chinchili VM, Fahy JV, Hawkins GA, Icitovic N, Israel E, Jarjour NN, King T, Kraft M, Lazarus SC, Lehman E, Martin RJ, Meyers DA, Peters SP, Sheerar D, Shi L, Sutherland ER, Szefler SJ, Wechsler ME, Sorkness CA, Lemanske RF Jr; NHLBI Asthma Clinical Research Network Investigators..

Am J Respir Crit Care Med. 2013 Jan 1;187(1):28-33. doi: 10.1164/rccm.201204-0750OC.

Items per page

Supplemental Content

Loading ...
Support Center